Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Determine TB-LAM lateral flow urine antigen assay for HIV-associated tuberculosis: recommendations on the design and reporting of clinical studies.

Lawn SD, Dheda K, Kerkhoff AD, Peter JG, Dorman S, Boehme CC, Nicol MP.

BMC Infect Dis. 2013 Sep 3;13:407. doi: 10.1186/1471-2334-13-407.

2.
3.

The diagnostic accuracy of urine-based Xpert MTB/RIF in HIV-infected hospitalized patients who are smear-negative or sputum scarce.

Peter JG, Theron G, Muchinga TE, Govender U, Dheda K.

PLoS One. 2012;7(7):e39966. doi: 10.1371/journal.pone.0039966. Epub 2012 Jul 9.

4.

Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults.

Nakiyingi L, Moodley VM, Manabe YC, Nicol MP, Holshouser M, Armstrong DT, Zemanay W, Sikhondze W, Mbabazi O, Nonyane BA, Shah M, Joloba ML, Alland D, Ellner JJ, Dorman SE.

J Acquir Immune Defic Syndr. 2014 Jul 1;66(3):270-9. doi: 10.1097/QAI.0000000000000151.

5.

Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study.

Lawn SD, Kerkhoff AD, Vogt M, Wood R.

Lancet Infect Dis. 2012 Mar;12(3):201-9. doi: 10.1016/S1473-3099(11)70251-1. Epub 2011 Oct 17.

6.

Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis.

Lawn SD, Kerkhoff AD, Vogt M, Wood R.

AIDS. 2012 Aug 24;26(13):1635-43. doi: 10.1097/QAD.0b013e3283553685.

PMID:
22555166
7.

Performance of urine lipoarabinomannan assays for paediatric tuberculosis in Tanzania.

Kroidl I, Clowes P, Reither K, Mtafya B, Rojas-Ponce G, Ntinginya EN, Kalomo M, Minja LT, Kowuor D, Saathoff E, Kroidl A, Heinrich N, Maboko L, Bates M, O'Grady J, Zumla A, Hoelscher M, Rachow A.

Eur Respir J. 2015 Sep;46(3):761-70. doi: 10.1183/09031936.00003315. Epub 2015 Jun 25.

PMID:
26113682
8.

Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial.

Peter JG, Zijenah LS, Chanda D, Clowes P, Lesosky M, Gina P, Mehta N, Calligaro G, Lombard CJ, Kadzirange G, Bandason T, Chansa A, Liusha N, Mangu C, Mtafya B, Msila H, Rachow A, Hoelscher M, Mwaba P, Theron G, Dheda K.

Lancet. 2016 Mar 19;387(10024):1187-97. doi: 10.1016/S0140-6736(15)01092-2. Epub 2016 Mar 10.

PMID:
26970721
9.

Predictors for MTB Culture-Positivity among HIV-Infected Smear-Negative Presumptive Tuberculosis Patients in Uganda: Application of New Tuberculosis Diagnostic Technology.

Nakiyingi L, Nonyane BA, Ssengooba W, Kirenga BJ, Nakanjako D, Lubega G, Byakika-Kibwika P, Joloba ML, Ellner JJ, Dorman SE, Mayanja-Kizza H, Manabe YC.

PLoS One. 2015 Jul 29;10(7):e0133756. doi: 10.1371/journal.pone.0133756. eCollection 2015.

10.

Diagnostic accuracy of a urine lipoarabinomannan strip-test for TB detection in HIV-infected hospitalised patients.

Peter JG, Theron G, van Zyl-Smit R, Haripersad A, Mottay L, Kraus S, Binder A, Meldau R, Hardy A, Dheda K.

Eur Respir J. 2012 Nov;40(5):1211-20. doi: 10.1183/09031936.00201711. Epub 2012 Feb 23.

11.

Rapid diagnosis of tuberculosis by detection of mycobacterial lipoarabinomannan in urine.

Hamasur B, Bruchfeld J, Haile M, Pawlowski A, Bjorvatn B, Källenius G, Svenson SB.

J Microbiol Methods. 2001 May;45(1):41-52.

PMID:
11295196
12.

Diagnostic accuracy of a urine lipoarabinomannan enzyme-linked immunosorbent assay for screening ambulatory HIV-infected persons for tuberculosis.

Gounder CR, Kufa T, Wada NI, Mngomezulu V, Charalambous S, Hanifa Y, Fielding K, Grant A, Dorman S, Chaisson RE, Churchyard GJ.

J Acquir Immune Defic Syndr. 2011 Oct 1;58(2):219-23. doi: 10.1097/QAI.0b013e31822b75d4.

13.

Clinical utility of a commercial LAM-ELISA assay for TB diagnosis in HIV-infected patients using urine and sputum samples.

Dheda K, Davids V, Lenders L, Roberts T, Meldau R, Ling D, Brunet L, van Zyl Smit R, Peter J, Green C, Badri M, Sechi L, Sharma S, Hoelscher M, Dawson R, Whitelaw A, Blackburn J, Pai M, Zumla A.

PLoS One. 2010 Mar 24;5(3):e9848. doi: 10.1371/journal.pone.0009848.

14.

High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay.

Lawn SD, Kerkhoff AD, Vogt M, Wood R.

J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):289-94. doi: 10.1097/QAI.0b013e318258c6af.

15.

Diagnostic accuracy of a point-of-care urine test for tuberculosis screening among newly-diagnosed HIV-infected adults: a prospective, clinic-based study.

Drain PK, Losina E, Coleman SM, Giddy J, Ross D, Katz JN, Walensky RP, Freedberg KA, Bassett IV.

BMC Infect Dis. 2014 Feb 26;14:110. doi: 10.1186/1471-2334-14-110.

16.

Lipoarabinomannan in urine during tuberculosis treatment: association with host and pathogen factors and mycobacteriuria.

Wood R, Racow K, Bekker LG, Middelkoop K, Vogt M, Kreiswirth BN, Lawn SD.

BMC Infect Dis. 2012 Feb 27;12:47. doi: 10.1186/1471-2334-12-47.

17.

Test characteristics and potential impact of the urine LAM lateral flow assay in HIV-infected outpatients under investigation for TB and able to self-expectorate sputum for diagnostic testing.

Peter J, Theron G, Chanda D, Clowes P, Rachow A, Lesosky M, Hoelscher M, Mwaba P, Pym A, Dheda K; TB-NEAT team.

BMC Infect Dis. 2015 Jul 9;15:262. doi: 10.1186/s12879-015-0967-z.

18.

Point-of-care lateral flow assays for tuberculosis and cryptococcal antigenuria predict death in HIV infected adults in Uganda.

Manabe YC, Nonyane BA, Nakiyingi L, Mbabazi O, Lubega G, Shah M, Moulton LH, Joloba M, Ellner J, Dorman SE.

PLoS One. 2014 Jul 7;9(7):e101459. doi: 10.1371/journal.pone.0101459. eCollection 2014.

19.

Blinded evaluation of commercial urinary lipoarabinomannan for active tuberculosis: a pilot study.

Daley P, Michael JS, Hmar P, Latha A, Chordia P, Mathai D, John KR, Pai M.

Int J Tuberc Lung Dis. 2009 Aug;13(8):989-95.

20.

Urine lipoarabinomannan point-of-care testing in patients affected by pulmonary nontuberculous mycobacteria--experiences from the Danish Cystic Fibrosis cohort study.

Qvist T, Johansen IS, Pressler T, Høiby N, Andersen AB, Katzenstein TL, Bjerrum S.

BMC Infect Dis. 2014 Dec 4;14:655. doi: 10.1186/s12879-014-0655-4.

Items per page

Supplemental Content

Write to the Help Desk